PMID- 36244795
OWN - NLM
STAT- MEDLINE
DCOM- 20221018
LR  - 20221018
IS  - 1880-313X (Electronic)
IS  - 0388-6107 (Linking)
VI  - 43
IP  - 5
DP  - 2022
TI  - Activation of STAT3 (signal transducer and activator of transcription 3) in 
      synovial tissues from the hip joint in the early stage of rapidly destructive 
      coxopathy.
PG  - 173-180
LID - 10.2220/biomedres.43.173 [doi]
AB  - Interleukin-6 signaling activates signal transducer and activator of 
      transcription 3 (STAT3), resulting in matrix metalloproteinase-3 (MMP-3) 
      production. The hip joints with rapidly destructive coxopathy (RDC) show rapid 
      chondrolysis, probably by increased MMP-3. This study aimed to elucidate STAT3 
      activation in the synovial tissues with joint destruction in the early stage of 
      RDC. Synovial tissues within 7 months from the disease onset were obtained from 
      four RDC patients with femoral head destruction and high serum levels of MMP-3. 
      RDC synovial tissues demonstrated the synovial lining hyperplasia with an 
      increase of CD68-positive macrophages and CD3-positive T lymphocytes. STAT3 
      activation was found in the synovial tissues by immunohistochemistry using 
      anti-phospho-STAT3 antibody. The majority of phospho-STAT3-positive cells were 
      the synovial lining cells and exhibited negative expression of the macrophage or 
      T cell marker. Treatment with CP690,550, a Janus Kinase inhibitor, resulted in a 
      decrease in phospho-STAT3-positive cells, especially with high intensity, 
      indicating effective suppression of STAT3 activation in RDC synovial tissues. 
      Inhibitory effect of CP690,550 could work through the Janus Kinase/STAT3 axis in 
      the synovial tissues in the early stage of RDC. Thus, STAT3 may be a potential 
      therapeutic target for prevention of joint structural damage in RDC.
FAU - Yasuda, Tadashi
AU  - Yasuda T
AD  - Department of Orthopaedic Surgery, Kobe City Medical Center General Hospital.
FAU - Hara, Shigeo
AU  - Hara S
AD  - Department of Pathology, Kobe City Medical Center General Hospital.
FAU - Yamashita, Shinnosuke
AU  - Yamashita S
AD  - Department of Orthopaedic Surgery, Kobe City Medical Center General Hospital.
FAU - Mitsuzawa, Sadaki
AU  - Mitsuzawa S
AD  - Department of Orthopaedic Surgery, Kobe City Medical Center General Hospital.
FAU - Tsukamoto, Yoshihiro
AU  - Tsukamoto Y
AD  - Department of Orthopaedic Surgery, Kobe City Medical Center General Hospital.
FAU - Takeuchi, Hisataka
AU  - Takeuchi H
AD  - Department of Orthopaedic Surgery, Kobe City Medical Center General Hospital.
FAU - Ota, Satoshi
AU  - Ota S
AD  - Department of Orthopaedic Surgery, Kobe City Medical Center General Hospital.
FAU - Onishi, Eijiro
AU  - Onishi E
AD  - Department of Orthopaedic Surgery, Kobe City Medical Center General Hospital.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biomed Res
JT  - Biomedical research (Tokyo, Japan)
JID - 8100317
RN  - 0 (Interleukin-6)
RN  - 0 (Janus Kinase Inhibitors)
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (STAT3 protein, human)
RN  - EC 2.7.10.2 (Janus Kinases)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Hip Joint
MH  - Humans
MH  - Interleukin-6
MH  - *Janus Kinase Inhibitors
MH  - Janus Kinases
MH  - *Matrix Metalloproteinase 3
MH  - STAT3 Transcription Factor/genetics
EDAT- 2022/10/17 06:00
MHDA- 2022/10/19 06:00
CRDT- 2022/10/16 21:23
PHST- 2022/10/16 21:23 [entrez]
PHST- 2022/10/17 06:00 [pubmed]
PHST- 2022/10/19 06:00 [medline]
AID - 10.2220/biomedres.43.173 [doi]
PST - ppublish
SO  - Biomed Res. 2022;43(5):173-180. doi: 10.2220/biomedres.43.173.